Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

PR Newswire February 26, 2019

Xenon Pharmaceuticals Outlines 2019 Key Milestones

GlobeNewswire January 6, 2019

Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

GlobeNewswire December 3, 2018

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

GlobeNewswire November 30, 2018

Investor Expectations to Drive Momentum within The York Water, Canon, Peak Resorts, Volt Information Sciences, LSI Industries, and Xenon Pharmaceuticals — Discovering Underlying Factors of Influence

GlobeNewswire November 15, 2018

Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

GlobeNewswire November 7, 2018

Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2018

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update

GlobeNewswire October 30, 2018

Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares

GlobeNewswire September 17, 2018

Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares

GlobeNewswire September 12, 2018

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

GlobeNewswire September 12, 2018

Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program

GlobeNewswire September 10, 2018

Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy

GlobeNewswire September 6, 2018

Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study

GlobeNewswire August 29, 2018

Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2018

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update

GlobeNewswire August 3, 2018

Xenon Pharmaceuticals Announces At-The-Market Equity Offering

GlobeNewswire July 12, 2018

Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

GlobeNewswire June 1, 2018

7 Stocks Moving In Tuesday's After-Hours Session

Benzinga.com  May 15, 2018

Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference

GlobeNewswire May 15, 2018